Prescriber is the leading UK journal for healthcare professionals focussing on prescribing and medicines management. The journal features articles on all areas of therapeutics and prescribing policy and is fully peer reviewed. The content is relevant and of interest to all prescribers and prescribing policy makers including GPs, pharmacists, nurses and hospital specialists. Access to all content is free to healthcare professionals following registration.
Latest News
NICE draft guidance advises against common painkillers for chronic primary pain
In new draft guidance for consultation, NICE has recommended that several commonly used painkillers should not be prescribed for chronic primary pain. The...Read moreOxford’s COVID-19 vaccine induces strong immune response
Oxford University's ChAdOx1 nCoV-19 vaccine against COVID-19 induces a strong immune response, according to interim results of a UK phase 1/2 trial,...Read more
EC grants conditional marketing authorisation for remdesivir
The European Commission has granted a conditional marketing authorisation for remdesivir (Veklury), for the treatment of COVID-19 in adults and adolescents...Read moreDexamethasone reduces mortality in patients with severe respiratory complications of COVID-19
Dexamathasone reduces death by up to one-third in hospitalised patients with severe respiratory complications of COVID-19, according to the latest results...Read more
EMA reinforces advice on continuation of ACE inhibitors and sartans during the pandemic
The EMA has restated its previous advice that patients should continue to use ACE inhibitors or angiotensin II-receptor blockers (ARBs, also known as sartans)...Read more
Featured Articles
The Scottish Polypharmacy Guidance app in practice
Medication reviews are an integral part of effective medicines optimisation. The NHS Scotland Polypharmacy Guidance – Medicines Review provides an app that is convenient to use in all care settings, giving users access to up-to-date, evidence-based guidance. Currently, pharmacists conduct medication reviews using a combination of personal experience and national guidance; however, there is no agreed protocol for this. In this scoping exercise, eight medication review pharmacists from two neighbouring trusts conducted medication reviews for 64 patients to explore how the clinical section of the app compared with their usual care in terms of identifying drug-related problems across various care settings.
Click here to view
Making sense of antisense oligonucleotide therapy
Unlike conventional medicines, antisense oligonucleotides (ASO) work by addressing the genetic changes underlying a disease. One ASO, nusinersen, is already on the market for the treatment of spinal muscular atrophy, and several more ASO therapies in development hold potential for other neurological and neuromuscular conditions, such as Duchenne muscular dystrophy.
Click here to view
“Alexa… what pills do I need to take today?”
Can personal digital assistants such as Amazon Alexa help to improve patients’ adherence to their medicines? Here, the authors discuss the potential and the limitations of this technology, and describe their pilot study in patients with diabetes and other underlying health conditions.
Click here to view
